DANISH BIO – DANSK BIOTEK organizes four major plenary meetings for our members throughout the year to increase our members' knowledge regarding specific biotech topics and to facilitate networking. The events usually take place in February, May, September and November.

We also organize approximately four "saloon" meetings annually. They are small, intimate, "meet the expert" meetings with typically 6-20 participants advocating more in-depth discussion and knowledge-sharing on specific themes.

News

<img data-lazyloaded="1" src="data:image/gif;base64,R0lGODdhAQABAPAAAMPDwwAAACwAAAAAAQABAAACAkQBADs=" width="300" height="79" class="logoImg animateRtGeneral" data-src="https://danskbiotek.dk/wp-content/uploads/2020/04/ymabs-300x79.jpg" /><noscript><img data-lazyloaded="1" src="data:image/gif;base64,R0lGODdhAQABAPAAAMPDwwAAACwAAAAAAQABAAACAkQBADs=" width="300" height="79" class="logoImg animateRtGeneral" data-src="https://danskbiotek.dk/wp-content/uploads/2020/04/ymabs-300x79.jpg" /><noscript><img width="300" height="79" class="logoImg animateRtGeneral" src="https://danskbiotek.dk/wp-content/uploads/2020/04/ymabs-300x79.jpg" />

Y-mAbs Therapeutics to Present At 39th Annual J.P. Morgan Healthcare Conference 06 January 2021

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical... Read more

2cureX appoints Fernando Andreu, an international Biotech executive, as new CEO 05 January 2021

2cureX is pleased to announce that Fernando Andreu has been appointed new CEO and will start latest on... Read more

Recording from Virtual Members’ Meeting on Vaccines December 11, 2020 04 January 2021

DANISH BIO – DANSK BIOTEK conducted its first virtual members’ meeting ever on December 11 on the... Read more

Lif og DANISH BIO – DANSK BIOTEKs undersøgelse af de kliniske forskningsaktiviteter i Danmark 2019 18 December 2020

ARTIKEL Antallet af private kliniske forsøg i Danmark står stille Trods flere års offentlig-privat... Read more

The Food and Drug Administration (FDA) grants IO Biotech breakthrough therapy designation for IO102 and IO103 in combination with anti-PD-1 in unresectable/metastatic melanoma 15 December 2020

IO Biotech today announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough... Read more

<img data-lazyloaded="1" src="data:image/gif;base64,R0lGODdhAQABAPAAAMPDwwAAACwAAAAAAQABAAACAkQBADs=" width="300" height="79" class="logoImg animateRtGeneral" data-src="https://danskbiotek.dk/wp-content/uploads/2020/04/ymabs-300x79.jpg" /><noscript><img data-lazyloaded="1" src="data:image/gif;base64,R0lGODdhAQABAPAAAMPDwwAAACwAAAAAAQABAAACAkQBADs=" width="300" height="79" class="logoImg animateRtGeneral" data-src="https://danskbiotek.dk/wp-content/uploads/2020/04/ymabs-300x79.jpg" /><noscript><img width="300" height="79" class="logoImg animateRtGeneral" src="https://danskbiotek.dk/wp-content/uploads/2020/04/ymabs-300x79.jpg" />

Y-mAbs Announces Update on DANYELZA® (naxitamab-gqgk) at ESMO 09 December 2020

NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more

<img data-lazyloaded="1" src="data:image/gif;base64,R0lGODdhAQABAPAAAMPDwwAAACwAAAAAAQABAAACAkQBADs=" width="300" height="79" class="logoImg animateRtGeneral" data-src="https://danskbiotek.dk/wp-content/uploads/2020/04/ymabs-300x79.jpg" /><noscript><img data-lazyloaded="1" src="data:image/gif;base64,R0lGODdhAQABAPAAAMPDwwAAACwAAAAAAQABAAACAkQBADs=" width="300" height="79" class="logoImg animateRtGeneral" data-src="https://danskbiotek.dk/wp-content/uploads/2020/04/ymabs-300x79.jpg" /><noscript><img width="300" height="79" class="logoImg animateRtGeneral" src="https://danskbiotek.dk/wp-content/uploads/2020/04/ymabs-300x79.jpg" />

Y-mAbs and Takeda Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) and Omburtamab in Israel 04 December 2020

Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) (the “Company” or “Y-mAbs”) a commercial-stage biopharmaceutical... Read more

LINK Medical acquires IRW, further expanding its clinical research services and expertise across the Nordic countries 04 December 2020

Press Release LINK Medical has today announced the acquisition of IRW Consulting AB (IRW), a Nordic CRO... Read more

<img data-lazyloaded="1" src="data:image/gif;base64,R0lGODdhAQABAPAAAMPDwwAAACwAAAAAAQABAAACAkQBADs=" width="300" height="79" class="logoImg animateRtGeneral" data-src="https://danskbiotek.dk/wp-content/uploads/2020/04/ymabs-300x79.jpg" /><noscript><img data-lazyloaded="1" src="data:image/gif;base64,R0lGODdhAQABAPAAAMPDwwAAACwAAAAAAQABAAACAkQBADs=" width="300" height="79" class="logoImg animateRtGeneral" data-src="https://danskbiotek.dk/wp-content/uploads/2020/04/ymabs-300x79.jpg" /><noscript><img width="300" height="79" class="logoImg animateRtGeneral" src="https://danskbiotek.dk/wp-content/uploads/2020/04/ymabs-300x79.jpg" />

FDA Approves Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of Neuroblastoma 27 November 2020

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical... Read more

Copyright 2020 DANISH BIO – DANSK BIOTEK. All rights reserved.

created by: Mastafu Design